As expected, the combination therapy of TRAIL and DTCD notably inhibited the tumor growth of the A2780 xenografts (Fig. 7A), with T/C value 27.5% and inhibition rate 70.5%, which was prominently stronger than TRAIL-administrated group (T/C value: 83.3%, inhibition rate: 10.2%), and DTCD-treated group (T/C value: 61.7.6%, inhibition rate: 31.9%) (Fig. 7B). The gene discussed is TNFSF10; the disease is neoplasm.